Terrific listening to our CEO Daphne Koller and Jeffrey Reid of the Regeneron Genetics Center compare notes on #AI, genetics, #DEI, and talent pathways. They reinforced the urgent task of improving medicines for patients on Regeneron's new podcast, "The Nucleus." It was great to kick off the series by dissecting the underappreciated revolution in human biology “to quantitatively measure biology at high fidelity and at a high scale” and what it means for drug discovery, plus much more. Here are a few of our favorite insights from Daphne’s conversation with Jeff: 1. Why ML is essential for data-driven biology: With the explosion of tools to measure biological systems at various scales, "there's just no way for the human mind to assimilate and extract the information." But Daphne noted that “while you can interrogate biology at the level of cells, ultimately what you care about is curing humans, not cells," which is why insitro incorporates high-content human clinical data into our discovery strategy. 2. Why genetic diversity opens new windows: The more diverse the data from human genetics, the more we can explore new findings for drug discovery. Daphne shared that “variants that are only relevant in a certain subset of the population are often new windows into disease.” This is why it’s so critical “to create larger, more diverse population cohorts and make sure that they are accessible to the broader research population.” 3. Why we are using a pipeline through platform approach: insitro is building a pipeline through platform and is taking inspiration from life sciences pioneers like Regeneron. Our ML analysis models are generating and prioritizing therapeutic hypotheses, which provide the foundation for a discovery engine that will build value again and again. Daphne talked about her excitement for building a platform “that allows us to generate new therapeutic hypotheses and turn them into medicines.” A big thank you to Jeff and Regeneron for inviting us to be part of the launch of The Nucleus. We're energized by discussions like these with fellow innovators who push the boundaries of science and technology to develop transformative new treatments for patients – and look forward to tuning in to future episodes. For a deeper dive, listen to the full episode of The Nucleus here: https://lnkd.in/etun97D7
Welcome to The Nucleus, our first audio blog exploring the science that inspires and intrigues us. First up, tune in to hear our host Jeffrey Reid, PhD, VP, Chief Data Officer, Regeneron Genetics Center (RGC) in conversation with Daphne Koller, PhD, Founder and CEO of insitro, examining how AI and ML are being applied to tackle some of the most pressing challenges in the biotech industry, from accelerating drug discovery to unlocking personalized therapeutics. Listen to the full audio blog here: https://bit.ly/4g0jiAt Stay tuned for future episodes of #TheNucleus, with rotating hosts from Regeneron.